S. Hahn

Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation

C. Koch, S. Evans, S. Hahn, 2001, American journal of clinical oncology.

Hypoxic Heterogeneity in Human Tumors

C. Koch, S. Evans, S. Hahn, 2001 .

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

W. Uhl, P. Höhn, M. Buchholz, 2022, Cancers.

Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles

C. Koch, W. Mckenna, J. Covey, 2001, Cancer Chemotherapy and Pharmacology.

Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level

Klaus Gerwert, Ibrahim Daho, Samir F El-Mashtoly, 2018, Scientific Reports.

Overexpression of Interleukin-4 in the Thyroid of Transgenic Mice Upregulates the Expression of Duox1 and the Anion Transporter Pendrin.

J. Dumont, F. Miot, B. Corvilain, 2016, Thyroid : official journal of the American Thyroid Association.

Detection of hypoxia in human squamous cell carcinoma by EF5 binding.

S M Evans, E M Lord, R. Weber, 2000, Cancer research.